Philogen (PHIL) H2 2024 earnings summary

Executive summary

• Revenues tripled year-over-year, reaching €77.5 million, mainly from third-party and customer contracts.

• Net profit was €45.3 million, a turnaround from a prior year loss, with EBITDA exceeding €41.6 million.

• Major clinical progress in oncology programs: Nidlegy (melanoma, non-melanoma skin cancer), Fibromun (glioblastoma, sarcoma), and advanced small molecule pipeline.

• Major licensing agreement signed with Sun Pharma for global commercialization of Fibromun.

• Positive net financial position of €102.184 million, up 69% year-over-year.

Financial highlights

• Total revenues rose to €77.653 million, a threefold increase year-over-year, driven by contract revenues.

• Operating expenditure was €36 million, up 20% year-over-year, mainly due to clinical and personnel costs.

• EBITDA exceeded €41.6 million; net profit was €45.3 million, benefiting from positive tax impacts.

• Cash and cash equivalents at year-end were €113.7 million, with no bank loans and only lease liabilities.

• Cash burn remained controlled at about €3 million per month.

Outlook and guidance

• Anticipates major clinical trial readouts in 2025 for multiple registration-enabling studies.

• Expects continued controlled OPEX growth, with no significant cost explosion due to in-house trial management.

• Maintains optionality for future capital raises but sees no immediate need given strong cash position.

• Ongoing expansion of clinical pipeline and R&D collaborations.